Toxicity and Radiation Dose of 2-[ 18F]-2-deoxy-D-glucose during Positron-Emission-Tomography;Toxizität und Strahlendosis von 2-[ 18F]-2-Desoxy-D-Glukose in der Positronenemissionstomographie

Acta Medica Austriaca

Volumn 25, Issue 1, 1998, Pages 1-6

  Ruhlmann, J ^a,e   Oehr, P ^a   Bender, H ^d   Kozak, B ^a   Willkomm, P ^d   Bechtold, V ^b   Lind, P ^c   Biersack, H J ^d  

^a PET Zentrum Bonn   (Germany)

^b KARLSRUHE INSTITUTE OF TECHNOLOGY   (Germany)

^c GENERAL HOSPITAL KLAGENFURT   (Austria)

^d UNIVERSITY OF BONN   (Germany)

^e PET Zentrum   (Germany)

Author keywords

FDG; Positron emission tomography (PET); Radiation dose; Toxicity

Indexed keywords

FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

COMPUTER ASSISTED EMISSION TOMOGRAPHY; GLUCOSE BLOOD LEVEL; HUMAN; METABOLISM; RADIATION DOSE; RADIATION MONITORING; REVIEW; BLADDER WALL; CANCER RISK; DOSIMETRY; DRUG METABOLISM; GENE MUTATION; INTRAVENOUS DRUG ADMINISTRATION; POSITRON EMISSION TOMOGRAPHY; RADIATION INJURY; TOXICITY TESTING; URINARY EXCRETION;

BLOOD GLUCOSE; FLUORODEOXYGLUCOSE F18; HUMANS; RADIATION DOSAGE; RADIATION MONITORING; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0031886328     PISSN: 03038173     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (16)

1. Baudot P, Jaque M, Robin M: Effect of a diazo-polyoxa-macroobicyclic complexing agent on the urinary elimination of lead in lead-poisened rats. Toxicol appl Pharmacol 1977;41:113-115.
2. Baumann M, Schäfer E, Grein H: Short term studies with the cryptating agent hexaoxa-diaza-bicyclo-hexacosane in rats. Arch Toxicol 1984;55 (suppl 7): 427-429.
3. Berry JJ, Hoffman JM, Steenbergen C, Baker JA, Floyd C, van Trigt P, Hanson MW, Coleman RE: Human Pathologic Correlation with PET in Ischemic and Nonischemic Cardiomyopathy. J Nucl Med 1993;34:39-47.
4. 18F) Fluoro-2-desoxy-D-glucose in adult humans. J Nucl Med 1991;32:707-712.
5. 18F-labeled 2-desoxy-2-fluoro-D-glucose as a radiopharmaceutical for measuring regional myocardial glucose metabolism in vivo: tissue distribution and imaging studies in animals. J Nucl Med 1977;18: 990-996.
6. Gallagher BM, Fowler JS, Gutterson NI, MacGregor RR, Wan CN, Wolf AP: Metabolic trapping as a principle of readiopharmaceutical design: Some factors responsible for the biodistribution of 2-Deoxy-2-[]fluoro-D-glucose. J Nucl Med 1978;19:1154-1161.
7. 18F] fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 1986;27:235-238.
8. Huiting JM, Visser FC, van Leeuwen GR, van Lingen A, Bax JJ, Heine RJ, Teule GJJ, Visser CA: Influence of high and low plasma insulin levels on the uptake of fluorine-18 fluorodeoxyglucose in myocardium and femoral muscle, assessed by planar imaging. Eur J Nucl Med 1955;22:1141-1148.
9. Jones SC, Alavi A, Christman D, Montanez I, Wolf AP, Reivich M: The radiation dosimetry of 2-F-18 fluoro-2-deoxy-D-glucose in man. J Nucl Med 1982;23:613-617.
10. Knuuti MJ, Nuutila P, Ruotsalainen U, Saraste M, Härkönen R, Ahonen A, Teräs M, Haarparanta M, Wegelius U, Haapanen A, Hartiala J, Voipio-Pulkki LM: Euglycemic hyperinsulemic clamp and oral glucose load in stimulating-myocardial glucose utilisation during positron emission tomography. J Nucl Med 1992;33:1255-1262.
11. 18F-fluorodeoxyglucose in PET studies. J Nucl Med 1991;32:699-706.
12. Meyer GJ, Waters SL, Coenen HH, Luxen A, Maziere B, Langström B: PET radiopharmaceuticals in Europe: current use and data relevant for the formulation of summaries of product characteristics (SPCs). Eur J Nucl Med 1995;22:1420-1432.
13. 18F] fluorodeoxyglucose method for the measurement of local cerebral glucose utilization in man. Circ Res 1979;44:127-137.
14. Schwaiger M, Büll U, Hör G, Hundeshagen H, Müller-Gärtner HW, Knapp WH, Notohamiprodjo G, Reiners C, Reske SN, Schicha H, vom Dahl J, Nienaber C, Sechtem U, Wolpers HG, Zimmermann R: Indikationen für die klinische Anwendung der Positronen-Emissions-Tomographie in der Kardiologie. Positionsbericht der Arbeitsgruppe PET-Kardiologie der Deutschen Gesellschaft für Nuklearmedizin und des Arbeitskreises Nuklearkardiologie der Deutschen Gesellschaft für Kardiologie. Z Kardiol 1996;85:453-468.
15. Thomas DG, Duthie HL: Use of 2 deoxy-D-glucose to test for the completeness of surgical vagotomy. Gut 1968;9:125-128.
16. Woosley RL, Kim YS, Huang KC: Renal tubular transport of 2-deoxy-D-glucose in dogs and rats. J Pharmacol Exp Ther 1970;173:13-20.